Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 223: | Line 223: | ||
[https://pmc.ncbi.nlm.nih.gov/articles/PMC6054918/ by Simon J Draper NIH] | [https://pmc.ncbi.nlm.nih.gov/articles/PMC6054918/ by Simon J Draper NIH] | ||
The development of highly effective and durable vaccines against the human malaria parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor have taught that achieving this goal will be challenging; however, recent innovation in malaria vaccine research and a diverse pipeline of novel vaccine candidates for clinical assessment provides optimism. With first-generation pre-erythrocytic vaccines aiming for licensure in the coming years, it is important to reflect on how next-generation approaches can improve on their success. | The development of highly effective and durable vaccines against the human malaria parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor have taught that achieving this goal will be challenging; however, recent innovation in malaria vaccine research and a diverse pipeline of novel vaccine candidates for clinical assessment provides optimism. With first-generation pre-erythrocytic vaccines aiming for licensure in the coming years, it is important to reflect on how next-generation approaches can improve on their success. | ||
=====RTS,S===== | |||
[https://www.malariavaccine.org/existing-vaccines/rtss by PATH] | |||
On October 6, 2021, the World Health Organization (WHO) recommended RTS,S/AS01, the world’s first malaria vaccine, for use in children at risk of malaria caused by Plasmodium falciparum. The WHO recommendation was informed by available evidence on RTS,S, including findings from a pilot implementation of the vaccine through routine childhood immunization in areas of Ghana, Kenya, and Malawi. | |||
